|
|
| Marissen, W. E.; Niezgoda, M.; Ellison, J.; Franka, R.; Kuzmina, N.; Kusmin, I.; Taylor, T.; Rupprecht, C.. |
| The currently recommended prophylaxis for individuals exposed to rabies virus is the combined administration of rabies vaccine and rabies immune globulin (RIG). However, limited supply hampers the availability of RIG, particularly in enzootic areas. To circumvent the global RIG limitation we aimed to develop a human monoclonal antibody combination, CL184, for rabies post-exposure prophylaxis (PEP) that would replace the plasma origin RIG. CL184 consists of two human IgG1 mAbs, CR57 and CR4098, which are directed against non-overlapping rabies virus (RV) glycoprotein epitopes. Previously, we have shown that the in vitro breadth of neutralization of CL184 against a large panel of street RV of various animal origins as well as in vivo protection by CL184 in a... |
| Tipo: Info:eu-repo/semantics/article |
|
| Ano: 2013 |
URL: http://www.revistamvez-crmvsp.com.br/index.php/recmvz/article/view/249 |
| |
